合作交流

研究成果 Research Outcomes

课题二

16. Bai Y, Li ZS, Zou DW, Wu RP, Yao YZ, Jin ZD, Ye P, Li SD, Zhang WJ, Du YQ, Zhan XB, Liu F, Gao J, Xu GM. Alarm features and age for predicting upper gastrointestinal malignancy in Chinese patients with dyspepsia with high background prevalence of Helicobacter pylori infection and upper gastrointestinal malignancy: an endoscopic database review of 102,665 patients from 1996 to 2006. Gut. 2010;59(6):722-8.

17. He J, Ma X, Zhao Y, Wang R, Yan X, Yan H, Yin P, Kang X, Fang J, Hao Y, Li Q, Dent J, Sung JJ, Zou D, Wallander MA, Johansson S, Liu W, Li Z. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China. BMC Gastroenterol. 2010 15;10:94.

18. Ma X, Zhao Y, Wang R, Yan X, Li Z, Zou D, He J. Epidemiology of gastroduodenal erosions in the general population: endoscopic results of the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol. 2010;45(12):1416-23.

19. Zou D, He J, Ma X, Chen J, Gong Y, Man X, Gao L, Wang R, Zhao Y, Yan X, Liu W, Wernersson B, Johansson S, Dent J, Sung JJ, Li Z. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis: the systematic investigation of gastrointestinal diseases in China (SILC). Scand J Gastroenterol. 2011;46(2):133-41.

20. Zhang, Ling ,Liu, Gang ,Han, Xu,Liu, Jie,Li, Guixiang,Zou, Duowu,Li, Zhaoshen,Inhibition of p38 MAPK activation attenuates esophageal mucosal damage in a chronic model of reflux esophagitis.,Neuro-Gastroenterology and Motility,2015,27(11):1648-1656

21. 王慧,陈帝,张玲,林寒,邹多武,胃食管反流病食管酸暴露和食管动力学变化特征,胃肠病学和肝病学杂志,2014,(09):1001-1003。

课题三

40. Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, Yuen HF, Tsao SW, He QY, Cheung AL. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. Clin Cancer Res. 2016; 22(5): 1243-55.

41. Zhang LY, Wu JL, Qiu HB, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis. 2016; 37(3): 320-32.

42. Li J, Zhang BZ, Qin YR, Bi J, Liu HB, Li Y, Cai MY, Ma S, Chan KW, Xie D, Guan XY. CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction. Oncotarget. 2016, [Epub ahead of print]

43. Li J, Li B, Xu WW, Chan KW, Guan XY, Qin YR, Lee NP, Chan KT, Law S, Tsao SW, Cheung AL. Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma,Expert Opin Ther Targets. 2015; 12(15): 1-12.

44. Zhu YH, Liu HB, Zhang LY, Zeng TT, Song Y, Qin YR, Li L, Liu LL, Li JB, Zhang BZ, Guan XY. Downregulation of LGI1 promotes tumor metastasis in esophageal squamous cell carcinoma. Carcinogenesis. 2014; 35(5): 1154-1161

45. Li B, Li J, Xu WW, Guan XY, Qin YR, Zhang LY, Law S, Tsao SW, Cheung AL. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget. 2014; 5(22): 11576-87.

46. Song Y, Li J, Zhu Y, Dai Y, Zeng T, Liu L, Li J, Wang H, Qin Y, Zeng M, Guan XY, Li Y. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget. 2014; 5(22): 11669-80.

47. Li JC, Li Y, Ai JY, Chen K, Zhu YH, Fu L, Qin YR, Wang LJ, Guan XY. Podoplanin positive cancer cells at the edge of esophageal squamous cell carcinomas are involved in invasion. Mol Med Rep. 2014; 10(3): 1513-8.

48. Lu P, Qiao J, He W, Wang J, Jia Y, Sun Y, Tang S, Fu L, Qin YR. Genome-wide gene expression profile analyses identify CTTN as a potential prognostic marker in esophageal cancer. PLoS One. 2014; 9(2): e88918.

课题四

1.Jin-Wu Wang, Chen-Tao Guan, Li-Li Wang, Ling-Yun Chang, Chang-Qing Hao, Bian-Yun Li, Ning Lu, Wen-Qiang Wei*. Natural history analysis of 101 severe dysplasia and esophageal carcinoma cases by endoscopy. Gastroenterology Research and Practice. 2017;9612854.

2.Jia-Jie Hao, De-Chen Lin, Huy Q Dinh, Anand Mayakonda, Yan-Yi Jiang, Chen Chang, Ye Jiang, Chen-Chen Lu, Zhi-Zhou Shi, Xin Xu, Yu Zhang, Yan Cai, Jin-Wu Wang, Qi-Min Zhan, Wen-Qiang Wei*, Benjamin P Berman*, Ming-Rong Wang* & H Phillip Koeffler*. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nature genetics. 2016;48(12):15

3.Wang M, Hao CQ, Ma Q, Song GH, Ma SR, Zhao DL, Zhao L, Li XQ, Wei WQ*. DNA image cytometry test for Esophageal Cancer Primary Screening in China: results from a population based multi-center study in high-risk areas in China. Chinese Journal of Cancer Research. 2016;28(4):76-84.

4.Yuan-jie Ding, Qing Ma, Fen Liu*, Lei Zhao, Wen-qiang Wei*. The potential use of salivary miRNAs as promising biomarkers for detection of cancer:A meta-analysis. PLoS One. 2016;11(11):e0166303.

5.Shang L, Hao JJ, Zhao XK, He JZ, Shi ZZ, Liu HJ, Wu LF, Jiang YY, Shi F, Yang H, Zhang Y, Liu YZ, Zhang TT, Xu X, Cai Y, Jia XM, Li M, Zhan QM, Li EM*, Wang LD*, Wei WQ*, Wang MR*. ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction. Oncotarget. 2016;7(17):24374-24382.

6.Wei WQ*, Chen ZF, He YT, Feng H, Hou J, Lin DM, Li XQ, Guo CL, Li SS, Wang GQ, Dong ZW, Abnet CC, Qiao YL. Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China. J Clin Oncol. 2015;33(17):1951-7.

7.Niu X, Wei WQ*, Hao CQ, Song GH, Li J, Hua ZL, Li YW, Chang J, Wang XZ, Zhao DL, Wang GQ, Hsieh E, Qiao YL. Evaluation of routine biopsies in endoscopic screening for esophagogastric junction cancer. World J Gastroenterol. 2014;20(17):5074-81.

8.Liu F, Wei WQ*, Cormier RT, Zhang ST, Qiao YL, Li XQ, Zhu ST, Zhai YC, Peng XX, Yan YX, Wu LJ, He D, He Y. Association of single nucleotide polymorphisms in the prostaglandin-endoperoxide synthase 2 (PTGS2) and phospholipase A₂group IIA (PLA2G2A) genes with susceptibility to esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(4):1797-802.

9.Zhao L, Wei WQ*, Zhao DL, Hao CQ, Lin DM, Pan QJ, Li XQ, Lei FH, Wang JW, Wang GQ, Shang Q, Qiao YL. Population-based study of DNA image cytometry as screening method for esophageal cancer. World J Gastroenterol. 2012;18(4):375-82.

10.魏文强*. 从林州食管癌高发现场看中国恶性肿瘤高发现场的历史作用与新时期发展方向. 中华肿瘤杂志.2016;38(9):717-20.

11.王孟, 李变云, 马山蕊, 于晓东, 马箐, 刘志才, 付方现, 张思维, 魏文强*. 2011年林州市肿瘤登记资料质量控制数据分析. 河南预防医学杂志.2016; 27(3):1-6.

12.马箐, 马山蕊, 王孟, 李新庆, 魏文强*. MicroRNAs与食管癌关系的研究进展.中国肿瘤.2016.(已接受)

13.王孟, 郝长青, 赵德利, 李变云, 王进武, 雷复华, 周瑞雪, 马山蕊, 马箐, 李琰琰, 冯昊, 李新庆, 魏文强*. 2005–2009年中国食管癌高发区河南省林州市、山东省肥城市食管癌及其癌前病变人群分布研究. 中华预防医学杂志. 2015;49(8):677-682.

14.魏文强*, 乔友林. 食管癌预防医学的重要研究进展. 浙江医学.2015;37(10):808.

15.冯昊, 宋国慧, 杨娟, 郝长青, 王孟, 李变云, 赵德利, 刘志才, 魏文强*, 乔友林. 中国农村食管癌高发区人群终生一次内镜筛查适宜年龄的卫生经济学评价. 中华肿瘤杂志.2015;37(6):476-480.

课题五

56. Chen K, Zhu Z, Zhang N, Cheng G, Zhang F, Jin J, Wu J, Ying L, Mao W*, Su D*. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma. Med Sci Monit. 2017 Sep 26;23:4619-4632.

57. Lai X, Gu Q, Zheng X, Liu G, Feng W, Lin X, Mao W. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study. J Cancer Res Ther. 2016 Oct;12(Supplement):89-95.

58. Ji W, Zheng W, Li B, Cao C, Mao W. Influence of body mass index on the long-term outcomes of patients with esophageal squamous cell carcinoma who underwent esophagectomy as a primary treatment: A 10-year medical experience. Medicine (Baltimore). 2016 Jul;95(29):e4204.

59. Pan Z, Mao W, Bao Y, Zhang M, Su X, Xu X.The long noncoding RNA CASC9 regulates migration and invasion in esophageal cancer. Cancer Med. 2016 Sep;5(9):2442-7. doi: 10.1002/cam4.770.

60. Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W*, Su D*. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016 May 24;7(21):30772-80.

61. Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W*. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget. 2016 May 23.

62. Lin G, Sun XJ, Han QB, Wang Z, Xu YP, Gu JL, Wu W, Zhang GU, Hu JL, Sun WY, Mao WM*. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol Lett. 2015;10(2):901-906.

63. Lin G, Han SY, Xu YP, Mao WM*. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. Dis Esophagus 2015.

64. Tao CJ, Lin G, Xu YP, Mao WM*. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015;6(11):1179-86.

共享与合作

数据共享条款

生物样本及原始数据信息由各参与单位在当地保管,原始数据备份后上传云平台。NCEC项目牵头单位负责整合、管理上传的数据并提交国家相关部门。外部单位需要利用相关资源时,需提出申请,获得批准后方可到相关单位提取资源。上述数据资源基于以下原则进行共享和使用: 1. 共享数据内容 NCEC项目可供共享的数据包括所有生物样本库及与生物样本匹配的流行病学、家族遗传、病理诊断、临床治疗及随访预后等相关数据,此外,还包括由NCEC项目数据经处理、分析所得到的数据、材料和结果等。共享数据不包括研究对象的个人身份信息。 2. 数据使用者资格 数据使用的申请者应是公认的学术机构或健康研究相关组织的工作人员,申请者需提供个人简历、团队平台基础及数据使用计划书,确保能够有效利用共享数据开展相关科学研究。 3. 数据申请与使用原则 (1) 申请者需依照研究目的申请和使用数据,不得申请超出研究目的之外的数据。仅有通过申请并签署《NCEC项目数据使用协议》后,方可使用项目数据,禁止未经许可擅自使用研究数据。 (2) 项目数据仅供医学研究目的使用,研究内容须与疾病或健康有关,不得用于商业目的。 (3) 按照项目的伦理要求和知情同意原则,所有数据将会采用匿名形式共享。数据申请者不得通过共享数据来识别或寻找调查对象,更不得泄露数据信息。 (4) 数据使用者需反馈所有由共享资源获得的研究分析结果,包括生物样本的各项指标的测算结果、原始数据的个案分析结果以及原始数据处理分析后的阳性结果和阴性结果等。同时,研究者需提供详细的说明资料,以便其他研究者能够充分理解和利用分析结果,以达到共建、共享的目标。 (5) 利用NCEC项目的生物样本和数据进行基金或项目申请时,需将NCEC项目相关人员(机构)作为共同申请者(机构)。 (6) 项目数据向中国申请合作者免费开放,国外申请合作者应支付相关费用,费用依申请的样本量大小、变量多少而定。

新参与单位申请条款

1. 高校、医院及科研机构均可申请加入NCEC项目团队。 2. 有意愿加入NCEC项目团队的单位需提交申请表,包括前期研究成果、已建立的高发现场和人群队列等信息,供NCEC项目执行委员会审核。 3. 新参与单位需承诺完成学术委员会、项目办公室及课题办公室安排及分配的科研任务,共同搭建食管癌专病队列生物样本库和数据库平台。 4. 新参与单位经NCEC项目执行委员会审核通过且签署协议书后方可加入NCEC项目团队,并可与其他已参与单位共同享有云平台生物样本和数据的使用权利,同时也必须履行数据共享相关义务(详见数据共享条款)。

申请流程

1. 数据共享申请流程 (1) 提交申请 申请者下载并填写《NCEC项目数据使用申请表》、《NCEC项目数据使用计划书》,附个人简历一同发邮件至NECE项目办公室邮箱(ncec_china@163.com)。若有缺漏的变量,需再次提交申请。 (2) 专家审核 申请材料经项目办公室递交至项目执行委员会审核,审核内容包括:①研究内容:研究方案的科学性、前沿性和创新性;②研究可行性:是否具备开展和实施研究的人员、平台基础和资金支持;③伦理审核:是否通过伦理审批,遵守知情同意及伦理原则。 (3) 签订协议 申请经项目执行委员会批准后,申请者须与NCEC项目学术委员会签订《NCEC项目数据使用协议》,盖章后将电子扫描件发邮件至ncec_china@163.com,纸质版邮寄至NCEC项目办公室(地址:xxxx)。 (4) 数据获取 为保证信息安全,申请者(机构)需购置U盘或硬盘寄于NCEC项目办公室,拷贝后寄给申请者(机构),禁止通过电子邮件、聊天工具等网络方式传输。生物样本需由申请方相关人员持《NCEC项目数据使用协议》复印件于相应样本库领取。 (5) 进度汇报 申请者在获得生物样本或数据后,需每6个月按照项目要求向项目办公室提交中期报告,项目结束前7日需提交所申请使用生物样本的各项指标的测算结果、原始数据的个案分析结果及项目总结报告。 2. 新参与单位申请流程 (1) 提交申请 拟加入NCEC项目单位下载并填写《NCEC项目新参加单位申请表》,发送邮件至NCEC项目办公室(ncec_china@163.com)。 (2) 专家审核 由NCEC项目执行委员会对申请单位进行资格审核。 (3) 签署协议 新参与单位通过NCEC项目执行委员会批准后,下载并填写《NCEC项目新参与单位合作协议书》,盖章后将电子扫描件发邮件至ncec_china@163.com,纸质版邮寄至NCEC项目办公室(地址:xxxx),方可正式加入NCEC项目团队。